Galmed Pharmaceuticals Total Assets Growth & History (GLMD)
Galmed Pharmaceuticals's total assets was $18.6M for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.6M | $127,000 | +0.69% |
| 2024 | 2024-12-31 | $18.5M | $1.9M | +11.25% |
| 2023 | 2023-12-31 | $16.6M | $68,000 | +0.41% |
| 2022 | 2022-12-31 | $16.6M | −$20.0M | −54.76% |
| 2021 | 2021-12-31 | $36.6M | −$15.8M | −30.12% |
| 2020 | 2020-12-31 | $52.4M | −$24.8M | −32.10% |
| 2019 | 2019-12-31 | $77.1M | −$13.5M | −14.86% |
| 2018 | 2018-12-31 | $90.6M | $71.0M | +361.23% |
| 2017 | 2017-12-31 | $19.6M | $3.2M | +19.41% |
| 2016 | 2016-12-31 | $16.4M | −$7.8M | −32.20% |
| 2015 | 2015-12-31 | $24.3M | −$8.7M | −26.31% |
| 2014 | 2014-12-31 | $32.9M | $32.8M | +19734.34% |
| 2013 | 2013-12-31 | $166,000 | — | — |
Galmed Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.3M | −$4.7M | −20.31% |
| Q1 2026 | 2026-03-31 | $16.0M | −$2.7M | −14.22% |
| Q4 2025 | 2025-12-31 | $18.6M | $127,000 | +0.69% |
| Q3 2025 | 2025-09-30 | $21.6M | — | — |
| Q2 2025 | 2025-06-30 | $22.9M | $9.6M | +71.98% |
| Q1 2025 | 2025-03-31 | $18.7M | — | — |
| Q4 2024 | 2024-12-31 | $18.5M | $1.9M | +11.25% |
| Q2 2024 | 2024-06-30 | $13.3M | $64,000 | +0.48% |
| Q4 2023 | 2023-12-31 | $16.6M | $68,000 | +0.41% |
| Q2 2023 | 2023-06-30 | $13.3M | −$10.3M | −43.68% |
| Q4 2022 | 2022-12-31 | $16.6M | −$20.0M | −54.76% |
| Q2 2022 | 2022-06-30 | $23.6M | −$28.8M | −54.95% |
| Q4 2021 | 2021-12-31 | $36.6M | −$15.8M | −30.12% |
| Q2 2021 | 2021-06-30 | $52.3M | −$12.5M | −19.31% |
| Q4 2020 | 2020-12-31 | $52.4M | −$24.8M | −32.10% |
| Q2 2020 | 2020-06-30 | $64.8M | −$20.3M | −23.81% |
| Q4 2019 | 2019-12-31 | $77.1M | −$13.5M | −14.86% |
| Q2 2019 | 2019-06-30 | $85.1M | −$9.7M | −10.26% |
| Q4 2018 | 2018-12-31 | $90.6M | $71.0M | +361.23% |
| Q2 2018 | 2018-06-30 | $94.8M | $84.8M | +845.92% |
| Q4 2017 | 2017-12-31 | $19.6M | $3.2M | +19.41% |
| Q2 2017 | 2017-06-30 | $10.0M | −$8.0M | −44.30% |
| Q4 2016 | 2016-12-31 | $16.4M | −$7.8M | −32.20% |
| Q2 2016 | 2016-06-30 | $18.0M | — | — |
| Q4 2015 | 2015-12-31 | $24.3M | −$8.7M | −26.31% |
| Q4 2014 | 2014-12-31 | $32.9M | $32.8M | +19734.34% |
| Q4 2013 | 2013-12-31 | $166,000 | — | — |
Galmed Pharmaceuticals total assets trends
Over the last five fiscal years, Galmed Pharmaceuticals's total assets decreased from $52.4M to $18.6M, a change of −$33.8M. The latest reported quarter, Q2 2026, shows $18.3M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗